Google
CAI Stock Price & Analysis — Caris Life Sciences, Inc. Common Stock (Healthcare >> Biotechnology)
CAI FAQ
What is CAI's P/E ratio?
Caris Life Sciences, Inc. Common Stock (CAI) currently trades at a P/E ratio of 41.68.
What is CAI's ROE?
Caris Life Sciences, Inc. Common Stock reports a Return on Equity (ROE) of 5.73%.
What is CAI's dividend yield?
Caris Life Sciences, Inc. Common Stock offers a dividend yield of 0.00%.
What is CAI's Quality Score?
Our AI rates CAI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CAI?
Our AI Timing Score for CAI is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CAI belong to?
Caris Life Sciences, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CAI AI Analysis Summary
Our AI summary for CAI: Caris Life Sciences, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 41.68, ROE of 5.73%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.32
Price
0.65
(4.15%)
Day Change
|
|
|---|
CAI, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.32 |
| PBV / Sector |
7.46 / 44,219.29
|
| Earning Per Share | 0.13 |
| PE / Sector |
41.68 / 19.28
|
| PEG or PE/Growth / Sector |
-1.53 / 1.23
|
| Average 1M Daily Value |
59.53 M
|
| Average 1W Daily Value |
70.04 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:17 |
| Symbol | CAI |
| Name | CARIS LIFE SCIENCES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 282.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,429.61 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 750 West John Carpenter Freeway, Irving, TX, United States, 75039
Phone: 866 771 8946
Website: https://www.carislifesciences.com
Employees: 1,846
Sector: Healthcare >> Biotechnology
Description: Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap